Pyrrolo[2,3-d]pyrimidine compounds
AssigneePfizer Inc.
InventorsMark J. Mitton-Fry, Pamela J. Berlinski, Matthew J. Birchmeier, Jerry W. Bowman, Andrea Joy Gonzales, Steven Glenn Kamerling, Donald Wayne Mann
Life of this patent
Estimating the term…
Abstract
Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.
Claims8
A compound of formula I:
- or a pharmaceutically acceptable salt thereof wherein R1 is C1-4alkyl optionally substituted with hydroxy.
A crystalline Form A of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt.
A process for preparing N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt Form A comprising reacting N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide with maleic acid.
Dependencies are inferred from the claim text.